首页> 外文期刊>The journal of immunology >Targeting MHC Class I Monomers to Dendritic Cells Inhibits the Indirect Pathway of Allorecognition and the Production of IgG Alloantibodies Leading to Long-Term Allograft Survival
【24h】

Targeting MHC Class I Monomers to Dendritic Cells Inhibits the Indirect Pathway of Allorecognition and the Production of IgG Alloantibodies Leading to Long-Term Allograft Survival

机译:将MHC I类单体靶向树突状细胞可抑制同种异体认知的间接途径以及导致同种异体移植长期存活的IgG同种抗体的产生。

获取原文
获取外文期刊封面目录资料

摘要

T cell depletion strategies are an efficient therapy for the treatment of acute rejections and are an essential part of tolerance induction protocols in various animal models; however, they are usually nonselective and cause wholesale T cell depletion leaving the individual in a severely immunocompromised state. So far it has been difficult to selectively delete alloreactive T cells because the majority of protocols either delete all T cells, subsets of T cells, or subpopulations of T cells expressing certain activation markers, ignoring the Ag specificity of the TCR. We have developed a model in which we were able to selectively deplete alloreactive T cells with an indirect specificity by targeting intact MHC molecules to quiescent dendritic cells using 33D1 as the targeting Ab. This strategy enabled us to inhibit the indirect alloresponse against MHC-mismatched skin grafts and hence the generation of IgG alloantibodies, which depends on indirectly activated T cells. In combination with the temporary abrogation of the direct alloresponse, we were able to induce indefinite skin graft survival. Importantly, the targeting strategy had no detrimental effect on CD4+CD25+FoxP3+ T cells, which could potentially be used as an adjunctive cellular therapy. Transplantation tolerance depends on the right balance between depletion and regulation. For the former this approach may be a useful tool in the development of future tolerance induction protocols in non-sensitized patients.
机译:T细胞耗竭策略是治疗急性排斥反应的有效方法,并且是各种动物模型中耐受诱导方案的重要组成部分。然而,它们通常是非选择性的,并导致批发性T细胞耗竭,使个体处于严重的免疫受损状态。到目前为止,由于大多数协议都忽略了TCR的Ag特异性,因此大多数协议要么删除所有T细胞,T细胞亚群或表达某些激活标记的T细胞亚群,要么很难选择性删除同种异体反应性T细胞。我们已经开发了一种模型,在该模型中,我们可以使用33D1作为靶向抗体,通过将完整的MHC分子靶向静止的树突状细胞,从而选择性地以间接特异性方式耗尽同种反应性T细胞。这种策略使我们能够抑制针对MHC不匹配的皮肤移植的间接同种异体反应,从而抑制IgG同种抗体的产生,这取决于间接激活的T细胞。结合直接过敏反应的暂时消除,我们能够诱导无限期的皮肤移植物存活。重要的是,靶向策略对CD4 + CD25 + FoxP3 + T细胞没有有害影响,可以潜在地用作辅助细胞疗法。移植耐受性取决于耗竭与调节之间的适当平衡。对于前者,该方法可能是开发未敏化患者未来耐受性诱导方案的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号